MRNA analyst scorecard · Moderna
37 rating changes on MRNA in the last 12 months. 50% of bullish calls were right at 30 days; 40% of bearish ones. Street grade D on 16 scored calls. Consensus target $120, 18% below the last close.
Graded through 2026-09-14 · last close $146.01 (2026-09-14). Rebuilt every morning.
Holds on MRNA, read: 0 cut to or raised to Hold (graded as the change) · 7 Holds whose target leaned 10%+ one way (graded that way, 42.9% right) · 12 true Holds, not graded.
Firm by firm
| Firm | Calls | Scored | Right | Accuracy | Grade | Avg 30d | Avg 90d | Latest | Date | Target |
|---|---|---|---|---|---|---|---|---|---|---|
| Goldman Sachs | 4 | 1 | 1 | — | — | +48.8% | +13.1% | Neutral | 2026-08-20 | $120 |
| JPMorgan | 2 | 1 | 1 | — | — | -8.0% | +89.8% | Underweight | 2026-08-21 | $77 |
| Piper Sandler | 3 | 3 | 2 | — | — | +12.1% | +51.5% | Overweight | 2026-06-26 | $77 |
| Morgan Stanley | 4 | 2 | 1 | — | — | -4.2% | +53.7% | Equal-Weight | 2026-08-20 | $89 |
| RBC Capital | 4 | 3 | 1 | — | — | +9.4% | +45.2% | Sector Perform | 2026-07-07 | $45 |
| Bank of America | 3 | 3 | 1 | — | — | +13.3% | +132.1% | Underperform | 2026-07-07 | $38 |
| Barclays | 3 | 0 | 0 | — | — | +5.1% | +57.0% | Equal-Weight | 2026-08-24 | $125 |
| UBS | 3 | 1 | 0 | — | — | -2.1% | +53.2% | Neutral | 2026-08-20 | $150 |
| Citigroup | 2 | 0 | 0 | — | — | +82.8% | +89.8% | Neutral | 2026-08-03 | $60 |
| Evercore ISI Group | 2 | 1 | 0 | — | — | +11.5% | +13.1% | In-Line | 2026-05-04 | $50 |
| Rothschild & Co | 1 | 0 | 0 | — | — | — | — | Sell | 2026-09-03 | $81 |
| Argus Research | 1 | 0 | 0 | — | — | — | — | Buy | 2026-08-28 | $180 |
| Wolfe Research | 1 | 0 | 0 | — | — | — | — | Peer Perform | 2026-08-25 | — |
| William Blair | 1 | 0 | 0 | — | — | — | — | Outperform | 2026-08-19 | — |
| Jefferies | 1 | 0 | 0 | — | — | +14.9% | +81.2% | Hold | 2025-12-12 | $30 |
| Leerink Partners | 1 | 1 | 0 | — | — | +47.1% | +109.5% | Underperform | 2025-11-21 | $18 |
| Needham | 1 | 0 | 0 | — | — | -11.2% | +57.9% | Hold | 2025-10-20 | — |
Dimmed rows have fewer than 4 scored calls on MRNA — too few to grade.
Every call, last 12 months
| Date | Firm | Change | Action | Graded as | Price at call | Run before | +30d | +60d | +90d | Target · 90d check | Hit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 | Rothschild & Co | Neutral → Sell | downgrade | Bearish | $148.87 | +161.2% | — | — | — | $81 | pending |
| 2026-08-28 | Argus Research | Hold → Buy | upgrade | Bullish | $137.99 | +153.2% | — | — | — | $180 | pending |
| 2026-08-25 | Wolfe Research | Underperform → Peer Perform | upgrade | Bullish · raised to Peer Perform | $158.83 | +193.8% | — | — | — | — | pending |
| 2026-08-24 | Barclays | Equal-Weight → Equal-Weight | maintained | Leans bearish · Equal-Weight, target -10% | $138.89 | +156.9% | — | — | — | $125 | pending |
| 2026-08-21 | JPMorgan | Underweight → Underweight | maintained | Bearish | $145.13 | +149.9% | — | — | — | $77 | pending |
| 2026-08-20 | Goldman Sachs | Neutral → Neutral | maintained | Leans bearish · Neutral, target -10% | $133.32 | +123.5% | — | — | — | $120 | pending |
| 2026-08-20 | UBS | Neutral → Neutral | maintained | Leans bullish · Neutral, target +12% | $133.32 | +123.5% | — | — | — | $150 | pending |
| 2026-08-20 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | Leans bearish · Equal-Weight, target -33% | $133.32 | +123.5% | — | — | — | $89 | pending |
| 2026-08-19 | William Blair | Market Perform → Outperform | upgrade | Bullish | $174.38 | +193.1% | — | — | — | — | pending |
| 2026-08-03 | Citigroup | Neutral → Neutral | maintained | True hold · target +8% | $55.14 | -30.9% | +173.5% | — | — | $60 | not graded |
| 2026-07-21 | Goldman Sachs | Neutral → Neutral | maintained | Leans bullish · Neutral, target +12% | $59.66 | -6.7% | +123.5% | — | — | $67 | ✓ |
| 2026-07-08 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | Leans bearish · Equal-Weight, target -47% | $73.80 | +55.0% | -19.8% | +90.2% | — | $39 | ✓ |
| 2026-07-07 | RBC Capital | Sector Perform → Sector Perform | maintained | Leans bearish · Sector Perform, target -43% | $79.77 | +68.2% | -32.5% | +75.9% | — | $45 | ✓ |
| 2026-07-07 | Bank of America | Underperform → Underperform | maintained | Bearish | $79.77 | +68.2% | -32.5% | +75.9% | — | $38 | ✓ |
| 2026-06-26 | Piper Sandler | Overweight → Overweight | maintained | Bullish | $67.27 | +41.3% | -17.3% | +136.1% | — | $77 | ✗ |
| 2026-06-08 | Bank of America | Underperform → Underperform | maintained | Bearish | $47.60 | -12.4% | +55.0% | +24.3% | +194.8% | $34 missed | ✗ |
| 2026-05-04 | UBS | Neutral → Neutral | maintained | True hold · target -4% | $47.30 | -3.9% | +3.7% | +72.9% | +16.6% | $45 missed | not graded |
| 2026-05-04 | Goldman Sachs | Neutral → Neutral | maintained | True hold · target +3% | $47.30 | -3.9% | +3.7% | +72.9% | +16.6% | $49 hit | not graded |
| 2026-05-04 | Evercore ISI Group | In-Line → In-Line | maintained | True hold · target +5% | $47.30 | -3.9% | +3.7% | +72.9% | +16.6% | $50 hit | not graded |
| 2026-05-04 | RBC Capital | Sector Perform → Sector Perform | maintained | Leans bearish · Sector Perform, target -19% | $47.30 | -3.9% | +3.7% | +72.9% | +16.6% | $38 missed | ✗ |
| 2026-04-02 | Barclays | Equal-Weight → Equal-Weight | maintained | True hold · target -2% | $49.20 | -1.3% | -3.9% | -6.4% | +47.4% | $48 missed | not graded |
| 2026-02-23 | Piper Sandler | Overweight → Overweight | maintained | Bullish | $50.29 | +3.2% | +6.5% | +0.9% | -6.5% | $69 missed | ✓ |
| 2026-02-17 | Goldman Sachs | Neutral → Neutral | maintained | True hold · target -6% | $43.93 | +5.0% | +19.2% | +24.3% | +9.5% | $41 missed | not graded |
| 2026-02-17 | RBC Capital | Sector Perform → Sector Perform | maintained | Leans bearish · Sector Perform, target -31% | $43.93 | +5.0% | +19.2% | +24.3% | +9.5% | $30 missed | ✗ |
| 2026-02-17 | Evercore ISI Group | In-Line → In-Line | maintained | Leans bearish · In-Line, target -20% | $43.93 | +5.0% | +19.2% | +24.3% | +9.5% | $35 missed | ✗ |
| 2025-12-12 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | True hold · target -5% | $29.46 | +10.3% | +14.9% | +42.5% | +81.2% | $28 missed | not graded |
| 2025-12-12 | Jefferies | Hold | initiated | True hold · target +1% | $29.46 | +10.3% | +14.9% | +42.5% | +81.2% | $30 missed | not graded |
| 2025-11-21 | Piper Sandler | Overweight → Overweight | reiterated | Bullish | $23.72 | -11.7% | +47.1% | +81.3% | +109.5% | $63 close | ✓ |
| 2025-11-21 | RBC Capital | Sector Perform → Sector Perform | maintained | True hold · target +5% | $23.72 | -11.7% | +47.1% | +81.3% | +109.5% | $25 hit | not graded |
| 2025-11-21 | Leerink Partners | Underperform → Underperform | maintained | Bearish | $23.72 | -11.7% | +47.1% | +81.3% | +109.5% | $18 missed | ✗ |
| 2025-11-10 | Bank of America | Underperform → Underperform | maintained | Bearish | $24.76 | -7.7% | +17.2% | +38.5% | +69.4% | $21 missed | ✗ |
| 2025-11-07 | Barclays | Equal-Weight → Equal-Weight | maintained | True hold · target +1% | $24.54 | -12.1% | +14.0% | +45.3% | +66.5% | $25 missed | not graded |
| 2025-10-23 | UBS | Buy → Buy | maintained | Bullish | $26.25 | +1.8% | -8.0% | +33.0% | +89.8% | $40 hit | ✗ |
| 2025-10-23 | JPMorgan | Underweight → Underweight | maintained | Bearish | $26.25 | +1.8% | -8.0% | +33.0% | +89.8% | $25 missed | ✓ |
| 2025-10-23 | Citigroup | Neutral → Neutral | maintained | True hold · target +6% | $26.25 | +1.8% | -8.0% | +33.0% | +89.8% | $28 hit | not graded |
| 2025-10-20 | Needham | Hold → Hold | reiterated | True hold | $27.24 | +7.9% | -11.2% | +24.1% | +57.9% | — | not graded |
| 2025-10-10 | Morgan Stanley | Equal-Weight → Equal-Weight | maintained | Leans bullish · Equal-Weight, target +19% | $26.83 | — | -7.7% | +5.3% | +26.2% | $32 hit | ✗ |
Also in Biotech
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How the grading works
Every sell-side rating change from the last 365 days is priced the day it lands and checked again 30, 60 and 90 days later. A call is a hit when the stock moved in the called direction at 30 days. Buy- and Sell-side ratings call their own direction. A Hold is read, not waved through: a downgrade to Hold is graded as a bearish call and an upgrade to Hold as a bullish one, and a maintained Hold whose price target sits 10%+ above the price leans bullish (10%+ below, leans bearish) and is graded that way. A Hold with a target close to the price is a true Hold and is not graded at all. Every call with a price target also gets a target check 90 days later: hit (reached it or within 5%), close (covered at least half the distance) or missed. A firm's accuracy on a single name prints only after 4 scored calls, and a firm gets its own page only after 10 scored calls across every covered name — below that a percentage is noise. "Run before the call" is the stock's move over the 30 calendar days before the rating landed. Data: Yahoo Finance rating history and daily closes, rebuilt each morning. Nothing on this page is advice.
Get the 7 AM brief
The AM take, today's docket and the Street's calls — one email, weekdays, before the open.